AstraZeneca Pharma India Ltd. NSE: ASTRAZEN | BSE: 506820

Expensive Performer

Download real time

8919.00 95.00 (1.08%)

34.73% Gain from 52W Low

10,009

NSE+BSE Volume

NSE 13 Feb, 2026 3:31 PM (IST)

Regulatory Approval

AstraZeneca gets CDSCO approval to import Imfinzi for advanced endometrial cancer treatment See details

AstraZeneca Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents